Expression of matrix metalloproteinases and their tissue inhibitors in the serum and cerebrospinal fluid of patients with HIV-1 infection and syphilis or neurosyphilis

Cytokine

Volumn 54, Issue 2, 2011, Pages 109-116

  Tsai, Hung Chin ^a   Ye, Shin Yu ^b   Kunin, Calvin M ^c   Lee, Susan Shin Jung ^a   Wann, Shue Ren ^a   Tai, Ming Hong ^d   Shi, Min Hong ^a   Liu, Yung Ching ^e   Chen, Yao Shen ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Acquire immunodeficiency syndrome; Matrix metalloproteinase; Meningitis; Syphilis; Tissue inhibitors of matrix metalloproteinase

Indexed keywords

BIOLOGICAL MARKER; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; REAGINIC ANTIBODY; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME DEFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MICROENVIRONMENT; MIXED INFECTION; NEUROSYPHILIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEX DIFFERENCE; TAIWAN; VIRUS PATHOGENESIS; ZYMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; NEUROSYPHILIS; SYPHILIS; TAIWAN; TISSUE INHIBITOR OF METALLOPROTEINASES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79953050566     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.02.007     Document Type: Article

References (58)

1. Department of Health and Human Services CfDCaP, National Center for HIV, STD and TB Prevention, Division of STD Prevention. Sexually transmitted diseases surveillance 2004 supplement: syphilis surveillance report. 2005. Atlanta: Department of Health and Human Services CfDCaP, National Center for HIV, STD and TB Prevention, Division of STD Prevention.
2. Centers for Disease Control and Prevention Primary and secondary syphilis - United States, 2003-2004. MMWR Morb Mortal Wkly Rep 2006, 55:269-273.
3. Centers for Disease Control and Prevention Primary and secondary syphilis among men who have sex with men - New York City, 2001. MMWR Morb Mortal Wkly Rep 2002, 51:853-856.
4. Sadiq S.T., McSorley J., Copas A.J., Bennett J., Edwards S.J., Kaye S. Et. al. The effects of early syphilis on CD4 counts and HIV-1 RNA viral loads in blood and semen. Sex Transm Infect 2005, 81:380-385.
5. Kofoed K., Gerstoft J., Mathiesen L.R., Benfield T. Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis 2006, 33:143-148.
6. Palacios R., Jimenez-Onate F., Aguilar M., Galindo M.J., Rivas P., Ocampo A., et al. Impact of syphilis infection on HIV viral load and CD4 cell counts in HIV-infected patients. J Acquir Immune Defic Syndr 2007, 44:356-359.
7. Flood J.M., Weinstock H.S., Guroy M.E., Bayne L., Simon R.P., Bolan G., et al. Neurosyphilis during the AIDS epidemic, San Francisco, 1985-1992. J Infect Dis 1998, 931-940.
8. Berry C.D., Hooton T.M., Collier A.C., Lukehart S.A. Neurologic relapse after benzathine penicillin therapy for secondary syphilis in a patient with HIV infection. N Engl J Med 1987, 316:1587-1589.
9. DiNubile M.J., Copare F.J., Gekowski K.M. Neurosyphilis developing during treatment of secondary syphilis with benzathine penicillin in a patient without serologic evidence of human immunodeficiency virus infection. Am J Med 1990, 88:45N-48N.
10. Workowski K.A., Berman S.M. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55:1-94.
11. Marra C.M., Maxwell C.L., Smith S.L., Lukehart S.A., Rompalo A.M., Eaton M., et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004, 189:369-376.
12. Libois A., De Wit S., Poll B., Garcia F., Florence E., Del Rio A., et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 2007, 34:141-144.
13. Tsai H.C., Liu S.F., Wu K.S., Liu Y.C., Shi M.H., Chen E.R., et al. Dynamic changes of matrix metalloproteinase-9 in patients with Klebsiella pneumoniae meningitis. Inflammation 2008, 31:247-253.
14. Tsai H.C., Chung L.Y., Chen E.R., Liu Y.C., Lee S.S., Chen Y.S., et al. Association of MMP-9 and TIMP-4 in CSF with blood brain barrier dysfunction in patients with eosinophilic meningitis caused by Angiostrongylus cantonensis. Am J Trop Med Hyg 2008, 78:20-27.
15. Leppert D., Lindberg R.L., Kappos L., Leib S.L. Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Rev 2001, 36:249-257.
16. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., Opdenakker G. Biochemistry and molecular biology of gelatinease B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol 2002, 37:375-536.
17. Latronico T., Liuzzi G.M., Riccio P., Lichtner M., Mengoni F., D'Agostino C., et al. Antiretroviral therapy inhibits matrix metalloproteinase-9 from blood mononuclear cells of HIV-infected patients. AIDS 2007, 21:677-684.
18. Crocker S.J., Pagenstecher A., Campbell I.L. The TIMPs tango with MMPs and more in the central nervous system. J Neurosci Res 2004, 75:1-11.
19. Amour A., Knight C.G., Webster A., Slocombe P.M., Stephens P.E., Knäuper V., et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000, 473:275-279.
20. Stetler-Stevenson W.G., Brown P.D., Onisto M., Levy A.T., Liotta L.A. Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990, 265:13933-13938.
21. Blavier L., DeClerck Y.A. Tissue inhibitor of metalloproteinases-2 is expressed in the interstitial matrix in adult mouse organs and during embryonic development. Mol Biol Cell 1997, 8:1513-1527.
22. Greene J., Wang M., Liu Y.E., Raymond L.A., Rosen C., Shi Y.E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996, 271:30375-30380.
23. Leco K.J., Apte S.S., Taniguchi G.T., Hawkes S.P., Khokha R., Schultz G.A., et al. Murine tissue inhibitor of metalloproteinases-4 (TIMP-4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997, 401:213-217.
24. Dollery C.M., McEwan J.R., Wang M., Sang Q.A., Liu Y.E., Shi Y.E. TIMP-4 is regulated by vascular injury in rats. Circ Res 1999, 84:498-504.
25. Wang M., Liu Y.E., Greene J., Sheng S., Fuchs A., Rosen E.M. Et. al. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997, 14:2767-2774.
26. Liu Y.E., Wang M., Greene J., Su J., Ullrich S., Li H., et al. Preparation and characterization of recombination TIMP-4. J Biol Chem 1997, 272:20479-20483.
27. Paemen L. Evaluation of gelatinases and IL-6 in the cerebrospinal fluid of patients with optic neuritis, multiple sclerosis and other inflammatory neurological diseases. Eur J Neurol 1994, 1:55-63.
28. Yushchenko M., Weber F., Mäder M., Schöll U., Maliszewska M., Tumani H., et al. Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated concentrations are primarily related to CSF cell count. J. Neuroimmunol 2000, 110:244-251.
29. Leppert D., Leib S.L., Grygar C., Miller K.M., Schaad U.B., Holländer G.A. Matrix metalloproteinase (MMP)-8 and MMP-9 in cerebrospinal fluid during bacterial meningitis: association with blood-brain barrier damage and neurological sequelae. Clin Infect Dis 2000, 31:80-84.
30. Leib S.L., Clements J.M., Lindberg R.L., Heimgartner C., Loeffler J.M., Pfister L.A., et al. Inhibition of matrix metalloproteinases and tumour necrosis factor alpha converting enzyme as adjuvant therapy in pneumococcal meningitis. Brain 2001, 124:1734-1742.
31. Leib S.L., Kim Y.S., Chow L.L., Sheldon R.A., Tauber M.G. Reactive oxygen intermediates contribute to necrotic andapoptotic neuronal injury in an infant rat model of bacterial meningitis due to group B streptococci. J. Clin. Invest 1996, 98:2632-2639.
32. Rosenberg G.A., Estrada E.Y., Dencoff J.E., Stetler-Stevenson W.G. Tumor necrosis factor-α-induced gelatinase B causes delayed opening of the blood-brain barrier: an expanded therapeutic window. Brain Res 1995, 703:151-155.
33. Rumbaugh J.A., Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006, 12:1023-1044.
34. Toborek M., Lee Y.W., Flora G., Pu H., András I.E., Wylegala E. Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 2005, 25:181-199.
35. McArthur J.C., Haughey N., Gartner S., Conant K., Pardo C., Nath A., et al. Human immunodeficiency virus-associated dementia: an evolving disease. J. Neurovirol 2003, 9:205-221.
36. Conant K., McArthur J.C., Griffin D.E., Sjulson L., Wahl L.M., Irani D.N. Cerebrospinal fluid concentrations of MMP-2, 7, and 9 are elevated in association with human immunodeficiency virus dementia. Ann. Neurol 1999, 46:391-398.
37. Sporer B., Paul R., Koedel U., Grimm R., Wick M., Goebel F.D., et al. Presence of matrix metalloproteinase-9 activity in the cerebrospinal fluid of human immunodeficiency virus-infected patients. J Infect Dis 1998, 178:854-857.
38. Liuzzi G.M., Mastroianni C.M., Santacroce M.P., Fanelli M., D'Agostino C., Vullo V., et al. Increased activity of matrix metalloproteinases in the cerebrospinal fluid of patients with HIV associated neurological diseases. J. Neurovirol. 2000, 6:156-163.
39. Yong V.W., Krekoski C.A., Forsyth P.A., Bell R., Edwards D.R. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998, 21:75-80.
40. Miller A., Shapiro S., Lahat N., Galboiz Y. Matrix metalloproteinases and their inhibitors in brain injury and repair. Brain disease: therapeutic strategies and repair 2002, 63-68. Martin Dunitz, UK. O. Abramsky, D.A.S. Comspton, A. Miller, G. Said (Eds.).
41. Sulik A., Chyczewski L. Immunohistochemical analysis of MMP-9, MMP-2 and TIMP-1, TIMP-2 expression in the central nervous system following infection with viral and bacterial meningitis. Folia Histochemica 2008, 46:437-442.
42. Keiseier B.C., Seifert T., Giovannoni G., Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 1999, 53:20-25.
43. Sulik A., Wojtkowska M., Oldak E. Elevated level of MMP-9 and TIMP-1 in the cerebrospinal fluid of children with Echovirus Type 30 and Mumps meningitis. Scand J Immunol 2008, 68:323-327.
44. Kolb S.A., Lahrtz F., Paul R., Leppert D., Nadal D., Pfister H.W., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in viral meningitis: upregulation of MMP-9 and TIMP-1 in cerebrospinal fluid. J Neuroimmunol 1998, 84:143-150.
45. Pagenstecher A., Stalder A.K., Kincaid C.L., Shapiro S.D., Campbell I.L. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 1998, 152:729-741.
46. Gijbels K., Galardy R.E., Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994, 94:2177-2182.
47. Welgus H.G., Campbell E.J., Curry J.D., Eisen A.Z., Senior R.M., Wilhelm S.M., et al. Neutral metalloproteinases produced by human mononuclear phagocytes. J Clin Invest 1990, 86:1496-1502.
48. Rosenberg G.A., Kornfeld M., Estrada E., Kelley R.O., Liotta L.A., Stetler-Stevenson W.G. TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase. Brain Res 1992, 576:203-207.
49. Kieseier B.C., Paul R., Koedel U., Seifert T., Clements J.M., Gearing A.J., et al. Differential expression of matrix metalloproteinases in bacterial meningitis. Brain 1999, 122:1579-1587.
50. Matsuura E., Umehara F., Hashiguchi T., Fujimoto N., Okada Y., Osame M. Marked increase of matrix metalloproteinase 9 in cerebrospinal fluid of patients with fungal or tuberculous meningoencephalitis. J Neurol Sci 2000, 173:45-52.
51. Azeh I., Mader M., Smirnov A., Beuche W., Nau R., Weber F. Experimental pneumococcal meningitis in rabbits: the increase of matrix metalloproteinase-9 in cerebrospinal fluid correlates with leucocyte invasion. Neurosci Lett 1998, 256:127-130.
52. Lee K.Y., Kim E.H., Yang W.S., Ryu H., Cho S.N., Lee B.I., et al. Persistent increase of matrix metalloproteinases in cerebrospinal fluid of tuberculous meningitis. J Neurol Sci 2004, 220:73-78.
53. Vaillant C., Didier-Bazes M., Hutter A., Belin M.F., Thomasset N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci 1999, 19:4994-5004.
54. Jaworski D.M., Fager N. Regulation of tissue inhibitor of metalloproteinase-3 (Timp-3) mRNA expression during rat CNS development. J Neurosci Res 2000, 61:396-408.
55. Chang C., Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11:S37-S43.
56. Bode W., Fernandez-Catalan C., Grams F., Gomis-Rüth F.X., Nagase H., Tschesche H. Insights into MMP-TIMP interactions. Ann NY Acad Sci 1999, 878:73-91.
57. Berger J.R. Neurosyphilis in human immunodeficiency virus type 1-seropositive individuals. Arch Neurol 1991, 48:700-702.
58. Davis L.E., Schmitt J.W. Clinical significance of cerebrospinal fluid tests for neurosyphilis. Ann Neurol 1989, 25:50-55.